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 Background: Endometriosis is a disabling disease of reproductive-age women. Dysmenorrhea, dyspareunia, and pelvic pain 
are the main symptoms of endometriosis. Its etiology is not clear. Endometriosis may have various causes, in-
cluding vitamin D deficiency, but its effect is controversial.
 Material/Methods: In this double-blind clinical trial, we enrolled patients with endometriosis diagnosed and treated by laparos-
copy, with scores of at least 3 for of dysmenorrhea and/or pelvic pain at 8 weeks after surgical treatment. 
They were randomly prescribed vitamin D (50 000 IU weekly for 12 weeks) or placebo. Severity of pain in the 
2 groups (placebo and treatment) was compared by VAS test at 24 weeks after surgical treatment.
 Results: There were 19 patients in the vitamin D group and 20 in the placebo group. Baseline characteristics in the 2 
groups were similar. Following the treatment with vitamin D or placebo, we did not find significant differences 
in severity of pelvic pain (p=0.24) and dysmenorrhea (p=0.45) between the 2 groups. Mean pelvic pain at 24 
weeks after laparoscopy in the vitamin D group was 0.84±1.74 and in placebo group it was 0.68±1.70 (p=0.513). 
Mean dysmenorrhea was 2.10±2.33 in the vitamin D group and 2.73±2.84 in the placebo group (p=0.45).
 Conclusions: After ablative surgery for endometriosis, vitamin D treatment did not have a significant effect in reducing dys-
menorrhea and/or pelvic pain.
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Background
Endometriosis is defined as growth of endometrial glands and 
stroma outside the uterine cavity. It affects at least 10% of 
reproductive-age women [1,2]. Endometriosis is a prevalent 
cause of infertility, pelvic pain, dysmenorrhea, and dyspareu-
nia in reproductive-age women. Its diagnosis is by inspection 
of the pelvis during laparoscopy [1]. In women with pelvic pain 
and infertility, the prevalence of endometriosis is as high as 
90% [3,4]. Pain and infertility can greatly impair quality of life 
in affected women.
Endometriosis mimics some autoimmune and malignant dis-
eases, including familial occurrence and immunological abnor-
malities in B and T cells, increased angiogenesis, invasion of 
endometrial cells to adjacent organs (e.g., bladder and bow-
els), and need for repeat surgeries due to recurrence [1,5–7]. 
Multiple mechanisms for etiology and improvement of endo-
metriosis are suggested and the treatments are based on these 
unclear mechanisms. Therefore, progestin, GNRH agonists and 
antagonists [1], and drugs related to lipid metabolism (e.g., 
Simvastatin) are used for treatment [8,9]. It has been shown 
that inflammation is important in the pathogenesis of endo-
metriosis [10], so endometriosis treatment should not be dif-
ferent from that of other inflammatory disorders [11]. There 
may be a correlation between vitamin D levels and the risk of 
polycystic ovarian disease, endometriosis, breast and ovarian 
cancer, increased arterial stiffness in older patients, and my-
asthenia gravis [12–18].
It has been found that vitamin D has a role in normal cellular 
growth regulation [19]. Vitamin D has immune regulatory ef-
fects in chronic inflammatory responses [20]. Vitamin D increas-
es anti-inflammatory cytokines production and decreases pro-
inflammatory cytokines [19–22]. Vitamin D induces apoptosis 
and suppression of angiogenesis in vitro and in vivo [25–28]. 
Although an indirect relationship between vitamin D and en-
dometriosis has been reported in multiple studies, here has 
been no published randomized clinical trial on endometriosis 
and vitamin D treatment in women.
We explored the relationship between vitamin D and endo-
metriosis in a double-blind, randomized clinical trial look-
ing at the effect of vitamin D supplementation on cessation 
of pain in proven endometriosis after laparoscopic diagnosis 
and treatment.
Material and Methods
This randomized, double-blind clinical trial was performed in a 
single tertiary university hospital from Nov 2014 to Feb 2016.
To find patients with endometriosis, we did laparoscopy for var-
ious indications, including ovarian cyst, infertility, pelvic pain, 
and dysmenorrhea. Laparoscopy was performed under gener-
al anesthesia, using the triple-puncture technique. Using lap-
aroscopy, the surgeons diagnosed patients with endometriosis 
and tried to excise or ablate all diseased tissue. The day before 
laparoscopy, a data collection form was completed by a physi-
cian, including the reason for laparoscopy, and the severity of 
pelvic pain and dysmenorrhea were estimated using a visual 
analogue scale test (VAS test), with a score of 0 being no pain 
and a score 10 being the worst pain ever experienced. The lap-
aroscopies were done by 2 gynecologic laparoscopic surgeons; 
both were involved in each operation and they recorded the 
severity of endometriosis according to the revised American 
Society for Reproductive Medicine (ASRM) classification [1].
In the patients with endometriosis in the second menses af-
ter laparoscopic diagnosis and treatment, the VAS test was 
repeated. Patients with VAS scores of at least 3 for dysmen-
orrhea and/or pelvic pain were invited to participate in this 
clinical trial, and after consultation we asked them to sign the 
informed consent. The dyspareunia score was not a criterion 
for entering the study because some of the patients were not 
married and had not had intercourse.
Inclusion criteria
Women aged 15–40 years with proven endometriosis by lap-
aroscopy and a VAS test score of 3 or more for dysmenor-
rhea and/or pelvic pain at second menses after operative 
laparoscopy.
Exclusion criteria
1.  Patients with vitamin D treatment in the last 6 months pri-
or to surgery;
2.  Patients with known systemic diseases (e.g., hypertension, 
diabetes, coronary, renal, and hepatic diseases);
3. Patients with known malignancy;
4. Menopausal women;
5.  Patients with hormonal treatment, including oral contracep-
tive pills, in the last 6 months.
After authorization by the university Ethics Committee, eli-
gible patients were assigned by simple randomization to re-
ceive either vitamin D or placebo. In the vitamin D group (D 
group), we prescribed oral vitamin D 50 000 iu/weekly for 12 
weeks (capsule D-Vigel, vitamin D3 50 000 iu, Daana Pharma 
Co. Tabriz-Iran) and in the placebo group (P group) we pre-
scribed 1 capsule of placebo (Daana Pharma Co. Tabriz-Iran) 
weekly for 12 weeks. Four weeks after the end of the inter-
vention (24 weeks after surgical treatment), the VAS test was 
repeated for the 2 groups.
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Statistical analysis
We analyzed the data using SPSS 18. We used the KS test (one-
sample Kolmogorov-Smirnov test) for normality of data distri-
bution, Levine’s test for equality of variances and independent 
samples, and the t test for equality of means for comparing 
quantitative normal data between the 2 groups. We used the 
paired-samples t test for comparing quantitative normal data 
between before and after treatment in each group and the 
Pearson chi-square test for matching and comparing categor-
ical variables between the 2 groups. Due to the small sam-
ple size, we conducted Mann-Whitney non-parametric analy-
sis between the 2 groups and Wilcoxon signed ranks test for 
comparing before and after treatment data in each group.
This study was funded and supported by Iran University of 
Medical Sciences (IUMS), grant no. 93–02–140–24388, IRCT 
code IRCT2013021912151N3.
Results
We did 146 laparoscopies for different indications in gynecologic 
patients, and endometriosis was diagnosed in 75. At the second 
menses after diagnostic and therapeutic laparoscopy, 40 cases 
met the inclusion criteria for our study. One did not signed the 
informed consent. The remaining 39 cases were randomly as-
signed in vitamin D (n=19) or placebo treatment (n=20) groups. 
One patient in the placebo group became pregnant at the third 
month after the operation and discontinued placebo treatment. At 
the end of the study, we had 19 patients in each group (Figure 1).
Table 1 shows a baseline comparison between the 2 study 
groups for general characteristics, reason for laparoscopy, se-
verity of endometriosis, and severity of dysmenorrhea and 
pelvic pain.
The mean age of study participants was 29.89±5.30 years. 
Causes of laparoscopy in women with endometriosis diagnosed 
by laparoscopy were dysmenorrhea (n=28), ovarian cyst (n=23), 
chronic pelvic pain (n=19), and infertility (n=9). In some pa-
tients, there was more than 1 reason for laparoscopy. Severity 
of endometriosis in 45% was moderate (n=17) and 47% had 
severe endometriosis (n=18). Before laparoscopy, the mean 
pelvic pain score in the vitamin D group was 4.05±3.45 and 
4.82±4.1(p=0.513) in the placebo group. Before laparoscopy, 
the mean dysmenorrhea pain score in the vitamin D group was 
7.37±2.61 and in placebo group it was 6.42±3.04 (p=0.325).
Table 2 shows a comparison between the 2 groups for severi-
ty of pelvic pain and/or dysmenorrhea at different time points 
(before laparoscopy, in second menses after laparoscopy, and 
at 24 weeks after laparoscopy). At the second menses after 
laparoscopy, there was no significant difference between the 2 
groups for pelvic pain (p=0.583) and dysmenorrhea (p=0.365), 
and at 24 weeks after laparoscopy there was no significant 
difference between mean pain scores in the 2 groups. Mean 
pelvic pain at 24 weeks after laparoscopy in the vitamin D 
group was 0.84±1.74 and in placebo group it was 0.68±1.70 
(p=0.513). Mean dysmenorrhea was 2.10±2.33 in the vitamin 
D group and 2.73±2.84 in the placebo group (p=0.45).
All of the patients had good cooperation for follow-up and con-
tinued their treatment until the end of the study.
Discussion
In this double-blind, randomized clinical trial, at 24 weeks after 
laparoscopic treatment of endometriosis there was no signifi-
cant difference between effect of vitamin D3 (cholecalciferol) 
and placebo on severity of dysmenorrhea and/or pelvic pain.
This is the first clinical trial on women with endometriosis to 
explore the possible relationship between vitamin D treatment 
and relief of endometriosis-related pain. Our literature search 
found only studies that were indirectly related to vitamin D 
and endometriosis [27–43].
The etiology of endometriosis is poorly understood, and many 
etiologic factors have been suggested, including the serum lev-
el of 1, 25-dihydroxy vitamin D3. 1, 25-dihydroxy vitamin D3 is 
a fat-soluble vitamin with an unclear role in endometriosis. It 
is suggested that nuclear vitamin D receptors can have a reg-
ulatory role in inflammation and can be used as an index of 
Figure 1. Flow diagram.
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Vitamin D group Placebo group Total P value
Number of subjects 19 19 38
Mean age (SD)  30.84 (5.79)  28.95 (4.71)  29.89 (5.30) P=0.276
Marital status P=0.179
Not married  5 (26.32%)  9 (47.37%)  14 (37%)
Married  14 (73.68%)  10 (52.63%)  24 (63%)
Total  19 (100%)  19 (100%)  38 (100%)
Indications for laparoscopy, infertility P=0.252
Absent  13 (68.42%)  16 (84.21%)  29 (76%)
Present  6 (31.58%)  3 (15.79%)  9 (24%)
Total  19 (100%)  19 (100%)  38 (100%)
Indications for laparoscopy, pelvic pain P=1
Absent  10 (52.63%)  9 (47.37%)  19 (50%)
Present  9 (47.37%)  10 (52.63%)  19 (50%)
Total  19 (100%)  19 (100%)  38 (100%)
Indications for laparoscopy, dysmenorrhea P=1
Absent  5 (13.15%)  5 (13.15%)  10 (26.31%)
Present  14 (36.84%)  14 (36.84%)  28 (73.68%)
Total  19 (100%)  19 (100%)  38 (100%)
Indications for laparoscopy, ovarian cyst P=0.5
Absent  7 (18.42%)  8 (21.05%)  15 (39.47%)
Present  12 (31.57%)  11 (57.89%)  23 (60.52%)
Total  19 (100%)  19 (100%)  38 (100%)
Severity of endometriosis P=0.626
Minimal  0 (0.00%)  1 (5.26%)  1 (3%)
Mild  1 (5.26%)  1 (5.26%)  2 (5%)
Moderate  10 (52.63%)  7 (36.84%)  17 (45%)
Sever  8 (42.11%)  10 (52.63%)  18 (47%)
Total  19 (100%)  19 (100%)  38 (100%)
Pelvic pain before laparoscopy (median and 
interquartile range)
 5 (0–7)  5 (0–9)  5 (0–8) P=0.513*
Dysmenorrhea pain score before laparoscopy (median 
and interquartile range)
 8 (6–10)  6 (5–10)  14 (5–10) P=0.325*
Mean BMI 22.46 23 P=0.257
Mean pelvic pain before laparoscopy (SD)  4.05 (3.45)  4.82 (4.1)  4.45 (3.76) P=0.513*
Mean dysmenorrhea pain score before laparoscopy 
(SD)
 7.37 (2.61)  6.42 (3.04)  6.89 (2.84) P=0.325*
Table 1. Baseline comparison.
* Mann-Whitney U test.
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cellular metabolic health [20]. A study on vitamin D receptor 
gene polymorphism in endometriosis compared 132 infertile 
women with endometriosis with 132 fertile women, reporting 
no significant difference and suggesting that vitamin D recep-
tor gene polymorphism does not play an important role in the 
pathogenesis of endometriosis [29].
In some studies, higher plasma levels of 1, 25-dihydroxy vita-
min D3 and higher intake of dairy foods was associated with 
lower risk of endometriosis [30,31]. Conversely, another study 
compared serum vitamin D levels of 87 women with endome-
triosis with 53 women without endometriosis; the mean se-
rum levels of 1, 25-dihydroxy vitamin D3 in women with and 
without endometriosis were 24.9±14.8 ng/ml and 20.4±11.8, 
respectively (P=0.05) and the study concluded that endometri-
osis is associated with higher serum levels of vitamin D [32]. A 
systematic review of 10 case-control studies and 1 cohort study 
on women’s diet found that women with endometriosis had 
lower consumption of vegetables and omega-3, and reported 
a significant association between diet and endometriosis [33].
Vitamin D binding protein (DBP) is a plasma glycoprotein that 
modulates immune and inflammatory responses and also con-
trols transport of vitamin D metabolites and bone develop-
ment [34]. In a study comparing 13 ectopic endometrial tis-
sues and 6 normal endometrial tissues, vitamin D binding 
protein was significantly higher in the ectopic endometrial tis-
sues (P<0.05) [35]. A systematic review of research from 1946 
to 2013 on vitamin D and endometriosis reported that women 
with endometriosis had higher serum levels of vitamin D bind-
ing protein [36]. Another study compared serum and peritoneal 
levels of DBP in 26 women with endometriosis and 17 women 
with other benign gynecological conditions and reported that 
women with endometriosis had higher serum levels of DBP 
than in the control group [37]. A study comparing urinary lev-
els of DBP in 57 women with endometriosis with levels in 38 
controls found that the urinary level of DBP was significantly 
higher in patients with endometriosis [38].
A study using a rat model of endometriosis reported that treat-
ment with vitamin D3 produced fibrosis and apoptosis in the 
stroma of tissues with endometriosis [28]. A study on induced 
endometriosis in adult Balb female mice reported that admin-
istration of 100 µg/kg/day Elocalcitol (a vitamin D receptor ag-
onist) for 3 weeks reduced total lesion weight [39].
Because a relationship between vitamin D and endometriosis 
has been suggested by multiple studies, and since there has 
been no randomized clinical trial on endometriosis and vitamin 
D treatment in women, we decided to explore this relationship. 
In the present study on endometriosis-related pain, we found 
no significant difference in results of vitamin D treatment vs. 
placebo at 24 weeks after surgical diagnosis and treatment.
Vitamin D is a fat-soluble vitamin mainly produced in the body 
from food and supplements and cutaneous sun exposure. Vitamin 
D deficiency is defined as serum 1.25-dihydroxy vitamin D3 levels 
under 20 ng/ml. Vitamin D deficiency is prevalent worldwide. In 
the USA, it is reported in 52% of black and Hispanic adolescents 
in Boston and in 48% of girls in Maine, and it is seen in 40–100% 
of elderly men and women in the USA and Europe [44]. A study 
in Germany found that 57% of people 18–79 years old were vi-
tamin D deficient [45]. The prevalence of vitamin D deficiency 
was reported to be 90% in healthy subjects in Delhi, India [46]. 
In a systematic review of 195 studies in 44 countries found that 
37.3% of studies found that the mean serum vitamin D levels 
were less than 20 ng/ml [44]. The prevalence in pregnant Turkish 
women was 81.4% [47]. In a study of high school students in 
Iran, the serum mean vitamin D level was 14.7±9.4 ng/ml [48]. 
In another study in university students in Shiraz, Iran, 51.2% of 
female students had low serum levels of vitamin D [49].
Because the incidence of vitamin D deficiency in Iran is high 
and we did not check the serum vitamin D levels in samples 
before intervention, it is possible that this dose and duration 
of vitamin D prescription was beneficial only for treatment of 






0.513* 4.82 (4.1) 4.05 (3.45)Mean pelvic pain (SD)Pain before laparoscopy
0.325* 6.42 (3.04) 7.37 (2.61)Dysmenorrhea pain (SD) Mean
0.583 1.89 (2.40) 1.53 (1.54)Mean pelvic pain (SD)Pain at second menses
0.365 4.42 (2.65) 3.84 (2)Dysmenorrhea pain (SD) Mean
0.24 0.68 (1.70) 0.84 (1.74)Mean pelvic pain (SD)Pain after medical intervention (24 
weeks after laparoscopy))
0.45 2.73 (2.84) 2.10 (2.33)Dysmenorrhea pain (SD) Mean
Table 2. Comparison between two groups for mean scores of severity of pain (VAS score).
* Mann-Whitney U test.
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In 1072 women attending an infertility center, the prevalence 
of low serum vitamin D3 levels was 89%. Vitamin D3 levels 
were reported to be positively associated with height and en-
dometriosis history [40].
An in vitro study compared the effect of vitamin D3 on 25 hu-
man endometriosis stromal cell cultures (ovarian endometrio-
ma) with the effect of vitamin D3 on culture of 20 endometri-
al samples of non-endometriosis women; vitamin D3 inhibited 
proliferation, invasion, and pro-inflammatory cytokine produc-
tion in endometriosis and reduced production of interleukin 6 
and other inflammatory cytokines that stimulate adhesion of 
endometrial cells to the peritoneal cavity [41].
A study on in vitro effects of vitamin D3 on human endometri-
osis stromal cells found that vitamin D3 significantly reduced 
interleukin 1b and tumor necrotizing factor-a inflammatory 
responses, and also reported fewer endometrial stromal cells 
and reduced DNA synthesis. The study found significantly low-
er serum vitamin D3 levels in severe endometriosis compared 
to normal controls and patients with mild endometriosis [42].
A study in Italy investigated the effect of vitamin D on primary 
dysmenorrhea. The samples were 40 women aged 18–40 years 
old with 4 consecutive painful periods in the past 6 months. 
They measured the serum levels of 25 hydroxy vitamin D with 
high-performance liquid chromatography. Then the women 
were randomized into a group of 20 women who received a 
single oral dose of 300 000 IU vitamin D (cholecalciferol) at 
5 days before their next menstrual cycle and another group 
of 20 women received placebo. There was a negative correla-
tion between the baseline dysmenorrhea pain score and the 
level of 25 hydroxy vitamin D3 (r=0.36, p=0.2). The research-
ers found a significant reduction of dysmenorrhea pain in the 
vitamin D group in comparison with the placebo group in the 
next 2 menstruations (p<0.01). They suggested this signifi-
cant reduction of dysmenorrhea pain in vitamin D prescrip-
tion group was due to decreased levels of pro-inflammatory 
cytokines and decreased the biological activity of prostaglan-
dins [43]. The samples were not assessed for existing endo-
metriosis. Because low levels of serum vitamin D are common 
in healthy Italian pre-menopausal women [43], these results 
only show that vitamin D was effective in relieving dysmen-
orrhea at least for 2 months after treatment in women with 
or without endometriosis and also in women with or without 
vitamin D deficiency.
Conclusions
There may be a relationship between vitamin D and pathogen-
esis of endometriosis, but in our study vitamin D was not effec-
tive in treatment of endometriosis-related pain. Larger clinical 
trials are needed to determine the possible effects of vitamin 
D supplementation in endometriosis treatment.
Study limitations
The first limitation of this study is the high prevalence of vita-
min D deficiency in our country and worldwide, meaning that 
a high percentage of our samples may have had vitamin D de-
ficiency, which may have affected the results of our research. 
The second limitation is the small sample size of our study.
Further clinical trials are needed on the role of vitamin D treat-
ment for endometriosis-related pain. Future studies should as-
sess the serum levels of vitamin D before enrolling study sub-
jects, and those with vitamin D deficiency should be excluded. 
Clinical trials with larger sample sizes will be able to produce 
more reliable results.
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